Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • UCLA • HR+ • NCI-CCC Breast Tumor Board Question
Would you use a platinum containing regimen such as docetaxel + carboplatin for an aggressive ER+ breast cancer in a patient with a deleterious mutation in ATM?
Answer from: Medical Oncologist at Academic Institution
We do not have any data on ATM germline mutation carriers in regards to platinum use. Therefore, the decision to use platinum should be made independently from the ATM mutation.
Sign in or Register to read more